CTSK and lysosomal storage disease: Moreover, altered heart and valve development was also noted in a transgenic line expressing a secreted variant of cathepsin K. Collectively, these data identify mislocalized cathepsin K as an initiator of the cardiac disease associated with this lysosomal disorder and establish cathepsin inhibition as a viable therapeutic strategy.